Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 3;2(7):e197863.
doi: 10.1001/jamanetworkopen.2019.7863.

Rates of New Persistent Opioid Use After Vaginal or Cesarean Birth Among US Women

Alex F Peahl  1   2 , Vanessa K Dalton  1   2   3 , John R Montgomery  4 , Yen-Ling Lai  5 , Hsou Mei Hu  5 , Jennifer F Waljee  4   5
Affiliations

Rates of New Persistent Opioid Use After Vaginal or Cesarean Birth Among US Women

Alex F Peahl et al. JAMA Netw Open. .

Erratum in

  • Error in Discussion.
    [No authors listed] [No authors listed] JAMA Netw Open. 2019 Aug 2;2(8):e1911235. doi: 10.1001/jamanetworkopen.2019.11235. JAMA Netw Open. 2019. PMID: 31433475 Free PMC article. No abstract available.

Abstract

Importance: Research has shown an association between opioid prescribing after major or minor procedures and new persistent opioid use. However, the association of opioid prescribing with persistent use among women after vaginal delivery or cesarean delivery is less clear.

Objective: To assess the association between opioid prescribing administered for vaginal or cesarean delivery and rates of new persistent opioid use among women.

Design, setting, and participants: This retrospective cohort study used national insurance claims data for 988 036 women from a single private payer from January 1, 2008, to December 31, 2016. Participants included reproductive age, opioid-naive women with 1 year of continuous enrollment before and after delivery. For participants with multiple births, only the first birth was included.

Exposures: Peripartum opioid prescription (1 week before delivery to 3 days after discharge) captured by pharmacy claims, including prescription timing and size in oral morphine equivalents. Multivariable adjusted odds ratios were estimated using regression models.

Main outcomes and measures: Rates of new persistent opioid use, defined as pharmacy claims for 1 or more opioid prescription 4 to 90 days after discharge and 1 or more prescription 91 to 365 days after discharge among women who filled peripartum opioid prescriptions.

Results: In total, 308 226 deliveries were included: 195 013 (63.3%) vaginal deliveries and 113 213 (36.7%) cesarean deliveries. Participant mean (SD) age was 31.3 (5.3) years, and 70 567 (51.0%) were white patients. Peripartum opioid prescriptions were filled by 27.0% of women with vaginal deliveries and 75.7% of women with cesarean deliveries. Among them, 1.7% of those with vaginal deliveries and 2.2% with cesarean deliveries had new persistent opioid use. By contrast, among women not receiving a peripartum opioid prescription, 0.5% with vaginal delivery and 1.0% with cesarean delivery had new persistent opioid use. From 2008 to 2016, opioid prescription fills decreased for vaginal deliveries from 26.9% to 23.8% (P < .001) and for cesarean deliveries from 75.5% to 72.6% (P < .001), and fewer women had new persistent use (vaginal delivery, from 2.2% to 1.1%; P < .001; cesarean delivery, from 2.5% to 1.3%; P < .001). The strongest modifiable factor associated with new persistent opioid use after delivery was filling an opioid prescription before delivery (adjusted odds ratio, 1.40; 95% CI, 1.05-1.87). For vaginal deliveries, receiving a prescription equal to or more than 225 oral morphine equivalents was associated with new persistent opioid use (adjusted odds ratio, 1.25; 95% CI, 1.06-1.48). Women who underwent cesarean delivery and had a hysterectomy were more likely to develop persistence (AOR, 2.75; 95% CI, 1.33-5.70), although women who underwent a nonelective (AOR, 0.97; 95% CI, 0.88-1.07) or repeat cesarean (AOR, 1.45; 95% CI, 0.93-2.28) were not more likely. For cesarean deliveries, risk factors were associated with patient attributes such as tobacco use (adjusted odds ratio, 1.82; 95% CI, 1.56-2.11), psychiatric diagnoses, history of substance use (adjusted odds ratio, 1.43; 95% CI, 1.10-1.86), and pain conditions.

Conclusions and relevance: The results of the present study suggested that opioid prescribing and new persistent use after vaginal delivery or cesarean delivery have decreased since 2008. However, modifiable prescribing patterns were associated with persistent opioid use for patients who underwent vaginal delivery, and risk factors following cesarean delivery mirrored those of other surgical conditions. Judicious opioid prescribing and preoperative risk screening may be opportunities to decrease new persistent opioid use after childbirth.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Dalton reported receiving grants from the Agency for Healthcare Research and Quality, the National Institute for Reproductive Health, the Blue Cross Blue Shield Foundation, and the National Cancer Institute and receiving personal fees from Bayer outside the submitted work. Dr Montgomery was supported by Obesity Surgery Scientist Fellowship Award T32-DK108740 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Waljee receives grant payments from the National Institute on Drug Abuse. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flowchart of Patient Inclusions and Exclusions
Only the first delivery was included for patients with more than 1 delivery.
Figure 2.
Figure 2.. Rates of New Persistent Opioid Use for Vaginal or Cesarean Delivery Over Time
Data points indicate mean values, and error bars indicate SD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: final data for 2017. Natl Vital Stat Rep. 2018;67(8):-. - PubMed
    1. Torio CM, Andrews RM; Healthcare Cost and Utilization Project (HCUP) Statistical Briefs; Agency for Healthcare Research and Quality (US) . National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
    1. Bateman BT, Franklin JM, Bykov K, et al. . Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol. 2016;215(3):353.e1-353.e18. doi:10.1016/j.ajog.2016.03.016 - DOI - PMC - PubMed
    1. Prabhu M, Garry EM, Hernandez-Diaz S, MacDonald SC, Huybrechts KF, Bateman BT. Frequency of opioid dispensing after vaginal delivery. Obstet Gynecol. 2018;132(2):459-465. doi:10.1097/AOG.0000000000002741 - DOI - PMC - PubMed
    1. Brummett CM, Waljee JF, Goesling J, et al. . New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. doi:10.1001/jamasurg.2017.0504 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances